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ABSTRACT 
Diabetes mellitus, a frequent metabolic complication in liver transplant recipients, may be 
produced by the diabetogenic effect of calcineurin inhibitors cyclosporine and tacrolimus. 
The aim of this study was to investigate the safety and metabolic effects of a gradual 
switch from cyclosporine or tacrolimus to mycophenolate mofetil among 12 diabetic liver 
transplant recipients. One patient was withdrawn from the study due to gastrointestinal side 
effects. Of the 11 remaining patients, cyclosporine or tacrolimus was completely 
withdrawn in five patients. Two patients developed suspected acute rejection episodes that 
were controlled by increasing the tacrolimus dosage. Glycosylated hemoglobin A1C and 
C-peptide levels were significantly lower at 3 and 6 months after the initiation of 
mycophenolate mofetil (P < .03 in all cases). Furthermore, urea and uric acid levels were 
significantly reduced after the change of treatment. In conclusion, a switch from 
cyclosporine/tacrolimus to mycophenolate mofetil may produce beneficial metabolic 
effects in diabetic liver transplant recipients, but poses a risk of graft rejection. 
 
 
ID ABETES MELLITUS (DM) is a frequent metabolic complication in liver transplant 
(LT) recipients. Despite the lack of universal agreement, some studies have observed 
worsened short- and mid-term survival among diabetic LT recipients.1–7 Furthermore, DM is 
a wellknown risk factor for cardiovascular disease, which is one of the leading causes of 
death of LT recipients in the long term.8 Calcineurin inhibitors (CI) also predispose to DM 
through islet cell toxicity, diminished insulin synthesis or release, as well as decreased 
peripheral insulin sensitivity.9 Mycophenolate mofetil (MMF) has proven to be useful as a 
CI-sparing agent. The use of MMF has allowed physicians to reduce cyclosporine exposure 
in LT recipients with renal functional impairment.10 Some patients have been maintained on 
MMF monotherapy, but this strategy poses the risk of graft rejection.11 The aim of the 
present study was to examine whether conversion to MMF for stable LT recipients with DM 
allows the reduction/withdrawal of CI and results in improve metabolic control. 
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 PATIENTS AND METHODS 
We performed a progressive switch from CI to MMF in stable LT recipients with DM who 
fulfilled the following inclusion criteria: (1) follow-up longer than 12 months after LT; (2) 
DM diagnosed by fasting serum glucose level above 126 mg/dL on 2 separate days and/or the 
need for antidiabetic therapy to achieve good glycemic control; (3) stable anti-diabetic 
therapy during the previous 3 months; and (4) the possibility of monthly follow-up. 
Exclusion criteria were: (1) graft rejection during the last 6 months; (2) steroid therapy in 
the last 3 months; (3) previous MMF therapy; (4) hemoglobin level < 10 g/dL; (5) white 
blood cell count (WBC) <2500/mm3; (6) platelet count < 60,000/mm3; (7) peptic ulcer 
disease or significant gastroesophageal reflux disease. 
MMF Therapy 
At the first visit, azathioprine was discontinued (in three patients that were receiving this 
drug) and MMF was started at a daily dose of 1500 mg. MMF dose was reduced to 1000 
mg/d in cases of hematologic toxicity (hemoglobin level < 10 g/dL, WBC count < 
2500/mm3, or platelet count < 60,000/mm3). The MMF dose was increased to 2000 mg/d if 
the baseline mycophenolic acid (MPA) levels were below 1.0 µg/mL after 30 days of MMF 
therapy with the initial dose. 
Adjustment of CI Therapy 
One month after initiation of MMF, the baseline dose of CI was reduced each month by 
25% to 35%. If serum aspartate aminotransferase (AST) levels increased >25%, the CI dose 
was not further reduced. In case of a greater increase in AST, the CI dose was increased 
until there was normalization of the AST. 
The following variables were recorded at baseline as well as 3 and 6 months after initiation of 
MMF: mean arterial pressure, complete blood count (CBC), liver function tests, urea, 
creatinine, fasting glucose, glycosylated hemoglobin A1C (HbA1C), C-peptide, fasting lipid 
profile, and dose of CI and MMF, as well as MPA levels. Monthly visits included recording 
of CBC and liver function tests. Drug therapy for DM, arterial hypertension, and dyslipidemia 
were maintained unchanged during the 6-month follow-up. 
 
Statistical Analysis 
Quantitative data are expressed as median values (interquartile range). Baseline data were 
compared with 3- and 6-month data using Wilcoxon test for paired data. A difference was 
considered statistically significant if the P value was less than .05. All statistical analyses 
were performed using SPSS for Windows, version 9.0 (SPSS Inc, Chicago, Ill, USA). 
 
RESULTS 
Of the 18 patients selected for the trial, six failed to give consent. One of the 12 patients 
discontinued MMF due to gastrointestinal side effects. Thus, 11 patients completed the 6-
month study. Ten had been transplanted for alcoholic cirrhosis and one for Budd-Chiari 
syndrome. All but one were men. Their median age was 62 (53–66) years. They had been 
transplanted 52 (33–76) months before the change in therapy. Seven were on tacrolimus 
monotherapy; two received tacrolimus and azathioprine; one, cyclosporine, and one, 
cyclosporine and azathioprine. Three patients were not receiving antidiabetic drugs, four 
were on oral hypoglycemic agents, one was on insulin, and three were on insulin as well as 
oral hypoglycemic agents. 
 
Change in Immunosuppressive Therapy 
At the end of 6-month follow-up, the daily dose of MMF was 1500 mg in six patients and 
2000 mg in five. Their mycophenolic acid levels were 2.4 (1.4–2.7) µg/mL; five patients 
were on MMF monotherapy. Overall the doses of CI were 20% (0%–40%) of baseline. 
 
Effect on Glucose Metabolism 
The effect of the altered immunosuppression on glucose metabolism is shown in Table 1. 
Mild and insignificant decreases in fasting glucose levels were observed at 3 and 6 months 
after change of therapy. HbA1C levels were significantly lower at 3 months but not at 6 
months. C-peptide levels were significantly lower at 6 months after MMF initiation. After 
the end of the 6-month period of follow-up, one patient who was free of CI had good 
glycemic control without antidiabetic drugs despite a previous requirement or insulin (10 
units/d) and acarbose. 
 
Effect on Renal Function, Uric Acid Levels, and Lipid Profile 
As shown in Table 2 serum urea and uric acid levels significantly decreased at 3 and 6 
months. Creatinine, cholesterol, and triglyceride levels did not change significantly. No 
changes in mean arterial pressure were observed. 
 
Side Effects 
As previously mentioned, one patient discontinued MMF within the first month due to 
gastrointestinal side effects. Four patients who had mild increases of AST (~50% over the 
upper limit of normal range) were maintained on reduced doses of CI. Two patients 
developed suspected graft rejection after reducing tacrolimus dose to 25% of baseline (from 
4 and 2 to 1 and 0.5 mg/d, respectively). Liver function tests improved after tacrolimus dose 
in-creases to 3 and 1 mg/d, respectively. The evolution of liver function tests is shown in 
Table 2. There was no case of hematological toxicity requiring MMF dose reduction. MMF 
therapy did not significantly change hemoglobin levels or WBC or platelet counts. 
 
DISCUSSION 
In this trial, we attempted to utilize MMF to reduce or withdraw CI, and thereby improve 
DM among a series of 
LT recipients. The effect of CI reduction on glucose metabolism was modest. We have 
observed a significant reduction in HbA1C at 3 months after the initiation of the change in 
therapy, but it did not maintain statistical significance at 6 months. Despite this small 
apparent benefit, it was sufficient to allow one patient to discontinue insulin and oral 
hypoglycemic agents while maintaining good glycemic control. The finding of a reduced C-
peptide level following the change of immunosuppression suggests improved insulin 
resistance following CI dose reduction. 
This strategy to change immunosuppression posed a risk of graft rejection. Previous 
experiences in LT recipients with renal functional impairment reported controversial 
results. In our experience, episodes of graft rejection were well controlled with an increase 
in CI,10 but others have observed a poor responses.12 In the present paper, two patients 
(18%) developed a rejection episode, both of which responded to increases in CI. No 
patient required steroid therapy. On the other hand, five patients (45%) are currently on 
MMF monotherapy with good graft function. 
Other potential metabolic benefits of a change in therapy relate to the renal toxicity of CI. 
Despite the fact that most of our patients displayed good renal function initially, conversion 
of immunosuppression resulted in significant decreases in urea and uric acid. The decreased 
uric acid levels way benefit LT recipients with hyperuricemia and gout. 
The modest effect of the change in immunosuppression on glucose metabolism described 
herein may be explained in part by the initially low doses of CI. Five of nine patients 
receiving tacrolimus were on baseline daily doses less than or equal to 2 mg/d. All of these 
nine patients displayed tacrolimus trough levels below 6 ng/mL. On the other hand, 
institution of MMF monotherapy at an earlier time may have posed a greater risk of 
rejection. A better strategy for patients who are in the early posttransplant period may be to 
combine low doses of CI with MMF, instead of attempting early MMF monotherapy. 
In conclusion, the switch from CI to MMF among diabetic LT recipients may help to 
improve metabolic control, but it is followed by a low risk of graft rejection. Careful 
follow-up and a gradual decrease in CI are more advisable strategies. 
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Table 1. Changes in Fasting Serum Glucose, HbA1C, and CPeptide Levels 3 and 6 Months 
After Initiation of MMF Therapy 
  Baseline 3months 6months 
Glucose 
(mg/dL) 
144(115–151) 125(100–148) 132(121–142) 
HbA1C   (%) 6.7(5.8–7.3) 6.2(5.6–7.1)* 6.4(5.8–7.3) 
   
C-peptide 
(ng/mL) 
3.0(1.8–5.1) 3.4(1.9–5.7) 1.8(1.2–4.6)** 
 
*P = .025 compared with baseline. **P = .029 compared with baseline. 
 
 
 
Table 2. Evolution of Urea, Creatinine, and Uric Acid Levels and Liver Function Tests 3 and 6  
Months After Initiation of MMF Therapy 
  
Baseline 
 
3 months 
  6 months 
 
Urea (g/L) 0.46(0.39–0.57) 0.42(0.32–0.46)a 0.41(0.32–0.50)b
 Creatinine 
(mg/dL) 
1.0(1.0–1.3) 1.1(0.9–1.2) 1.0(0.9–1.2) 
 
Uric acid 
(mg/dL) 
6.4(4.8–7.4) 5.2(4.5–5.7)c 5.3(4.8–6.3)d
 
(14–25)eALT (IU/L) 15(13–20) 17(14–36) 20  
AST (IU/L) 19(14–28) 25(17–30) 25(16–38)  
AP (IU/L) 108(99–137) 116(104–196) 116  (96–194) 
 GGTP (IU/L) 19(15–37) 33(15–103) 27(19–51) 
Bilirubin 
(mg/dL) 
0.77(0.66–1.17) 0.82(0.69–1.08) 0.96  
 
(0.81–1.18) 
aP = .01 compared with baseline; bP = .028 compared with baseline; cP = .016 compared to 
baseline; dP = .04 compared with baseline; eP = .021 as compared with baseline. 
ALT: alanine aminotransferase; AST: aspartate aminotransferase; AP: alkaline phosphatase; 
GGTP: gamma-glutamyl transpeptidase. 
 
